Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157935 · ClinicalTrials.gov registry record · Phase 3
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,026
- Enrollment target
NCT02157935: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02157935 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,026 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02157935, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,026 participants
- Enrollment target
Study Summary
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
Primary Outcome
The annual COPD exacerbation rate was analyzed and compared between two arms. Annual exacerbation rate for each subject is defined as number of exacerbations divided by duration of randomized treatment period in years. The annual COPD exacerbation rate of Symbicort group was compared with annual rate of Formoterol group. The rate ratio of Symbicort vs. Formoteroal was assessed by a negative binomial model. Exacerbations, that met the modified Anthonisen criteria and duration ≥2 days were clas
Interventions
- DRUG Symbicort
- DRUG Formoterol turbohaler
- OTHER Placebo for Symbicort pMDI
- OTHER Placebo for Formoterol Turbohaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,026 participants |
| Start Date | 2014-06-27 |
| Est. Completion | 2016-02-08 |
| Phase | Phase 3 |
What the finished NCT02157935 record still lists
NCT02157935 is an interventional study that assigns participants to a tested intervention. Its 2,026 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 4 interventions - of which Symbicort is the first listed.
NCT02157935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02157935 about?
NCT02157935 is a clinical study titled "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease". Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT02157935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,026 participants. The study started on 2014-06-27. Estimated completion is 2016-02-08.
What interventions are being tested in trial NCT02157935?
The interventions under investigation include: Symbicort (DRUG), Formoterol turbohaler (DRUG), Placebo for Symbicort pMDI (OTHER), Placebo for Formoterol Turbohaler (OTHER).
Who is sponsoring clinical trial NCT02157935?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02157935's enrollment target sits among peer trials
2,026 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
- NCT05625659 · 2,032 participants · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI